dopamine hydrochloride 40 mg/ml concentrate for soln for inf
hospira uk limited - dopamine hydrochloride - concentrate for soln for inf - 40 mg/ml - adrenergic and dopaminergic agents
dopamine 40mg/ml sterile concentrate
hospira uk limited - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy
dopamine 200mg/5ml solution for infusion ampoules
pfizer ltd - dopamine hydrochloride - solution for infusion - 40mg/1ml
dopamine 200mg/5ml concentrate for solution for infusion ampoules
advanz pharma - dopamine hydrochloride - solution for infusion - 40mg/1ml
dopamine 800mg/5ml solution for infusion ampoules
advanz pharma - dopamine hydrochloride - solution for infusion - 160mg/1ml
dopamine hydrochloride 40 mg/ml sterile concentrate
pfizer healthcare ireland - dopamine hydrochloride - concentrate for solution for infusion - 40 milligram(s)/millilitre - adrenergic and dopaminergic agents; dopamine
dopaine (sterile dopamine concentrate 40mgml)
ain medicare sdn. bhd. - dopamine hydrochloride -
dopamine hydrochloride 40mg/ml sterile concentrate
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy
dopamine injection 200mg/5ml solution for injection, concentrate for
epinephrine injection
bpi labs, llc - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. none risk summary prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, does not identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are risks to the mother and fetus associated with epinephrine use during labor or delivery (see clinical considerations ). in animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis, resulted in adverse developmental effects (including gastroschisis, embryonic lethality, and delayed skeletal ossification) at doses approximately 2 times the maximum recommended daily intramuscular, subcutaneous, or intravenous dose (see data ). the estimated background risk of major birth defects and miscarriage